2. Academic Validation
  3. Poor removal of tedizolid during continuous hemodiafiltration: experiments using an in vitro continuous hemodiafiltration model

Poor removal of tedizolid during continuous hemodiafiltration: experiments using an in vitro continuous hemodiafiltration model

  • J Pharm Health Care Sci. 2023 Nov 14;9(1):37. doi: 10.1186/s40780-023-00307-9.
Satoshi Yoshikawa 1 2,  Shinichi Yoshikawa 3,  Akira Sato 3 4,  Tsukasa Matsumoto 3 4
Affiliations

Affiliations

  • 1 Faculty of Pharmacy, Iryo Sosei University, 5-5-1 Iino, Chuo-Dai, Iwaki, Fukushima, 970-8551, Japan. yoshikawa.satoshi@isu.ac.jp.
  • 2 Graduate School of Life Science and Technology, Iryo Sosei University, 5-5-1 Iino, Chuo-Dai, Iwaki, Fukushima, 970-8551, Japan. yoshikawa.satoshi@isu.ac.jp.
  • 3 Faculty of Pharmacy, Iryo Sosei University, 5-5-1 Iino, Chuo-Dai, Iwaki, Fukushima, 970-8551, Japan.
  • 4 Graduate School of Life Science and Technology, Iryo Sosei University, 5-5-1 Iino, Chuo-Dai, Iwaki, Fukushima, 970-8551, Japan.
PMID: 37957772 DOI: 10.1186/s40780-023-00307-9
Abstract

Background: Tedizolid is an Oxazolidinone anti-MRSA drug with included in the National Health Insurance Drug Price List in 2018. The effect of hemodialysis on tedizolid phosphate concentrations has been reported; pre-dialysis concentrations decreased by 10% compared to post- dialysis concentrations. However, the material of the dialysis membrane remains unknown. In addition, there have been no reports on the effects of continuous hemodiafiltration. In this study, we investigated the effects of continuous hemodiafiltration on tedizolid using two types of dialysis membranes made of different Materials.

Methods: The adsorption of tedizolid, linezolid, and vancomycin to two different dialysis membranes was investigated, and the clearance of each drug was calculated by experiments using an in vitro continuous hemodiafiltration model.

Results: The adsorption of tedizolid, linezolid, and vancomycin on the dialysis membranes was examined, and no adsorption was observed. Experimental results from the continuous hemodiafiltration model showed that linezolid and vancomycin concentrations decreased over time: after two hours, the respective decreases were 26.48 ± 7.14% and 28.51 ± 2.32% for polysulfone membranes, respectively. The decrease was 23.57 ± 4.95% and 28.73 ± 5.13% for the polymethylmethacrylate membranes, respectively. These results suggested that linezolid and vancomycin were eliminated by continuous hemodiafiltration. In contrast, tedizolid phosphate and tedizolid concentrations decreased slightly in the polysulfone and polymethylmethacrylate membranes. The decrease in concentrations were 2.10 ± 0.77% and 2.97 ± 0.60% for the polysulfone membranes, respectively. For the polymethylmethacrylate membranes, the decrease in concentration were 2.01 ± 0.88% and 1.73 ± 0.27%, respectively.

Conclusion: These results suggested that tedizolid should not be considered for dose control during continuous hemodiafiltration.

Keywords

Continuous hemodiafiltration; Methicillin-resistant Staphylococcus aureus; Tedizolid.

Figures
Products